Cencora — Feb 5, 2025 release

Additional expectations now include: • Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent, from the previous range of 5 to 6.5 percent; ◦ U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent, from the previous range of 5 to 6.5 percent; ◦ International Healthcare Solutions segment as reported operating income growth to be flat, from the previous range of 5 to 6.5 percent; ▪ On a constant currency basis, International Healthcare Solutions segment operating income growth to be approximately 5 percent; • Net interest expense to be in the range of $290 million to $310 million, from the previous range of $150 million to $170 million; and • Weighted average diluted shares outstanding is expected to be under 196 million, from the previous expectation of approximately 196 million. For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation for investors. Dividend Declaration     The Company’s Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable March 3, 2025, to stockholders of record at the close of business on February 14, 2025. Conference Call & Slide Presentation The Company will host a conference call to discuss its operating results at 8:30 a.m. ET on February 5, 2025. A slide presentation for investors has also been posted on the Company’s website at investor.cen